Systemic immune-inflammation index as a biomarker for stroke prognosis: insights from a multi-time point analysis.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-08-01 Epub Date: 2025-08-08 DOI:10.1080/17520363.2025.2540760

Yanan Wang, Jiaojiao Wang, Fengmei Tian, Mengyun Peng, Xiaomin Ma, Dahong Zheng, Xiaoxiao Li, Jingya Jiao, Liping Zheng, Zhengbao Zhu, Shu Ji, Daoxia Guo

{"title":"Systemic immune-inflammation index as a biomarker for stroke prognosis: insights from a multi-time point analysis.","authors":"Yanan Wang, Jiaojiao Wang, Fengmei Tian, Mengyun Peng, Xiaomin Ma, Dahong Zheng, Xiaoxiao Li, Jingya Jiao, Liping Zheng, Zhengbao Zhu, Shu Ji, Daoxia Guo","doi":"10.1080/17520363.2025.2540760","DOIUrl":null,"url":null,"abstract":"Aims: This study aimed to investigate the association between the systemic immune-inflammation index (SII) and prognosis trajectories in ischemic stroke(IS).Methods: Patients from two tertiary hospitals in Suzhou were included in this study. SII was calculated as neutrophils×platelets/lymphocytes, and patients were categorized into quartiles based on SII values. Latent class growth modeling (LCGM) was employed to describe the trajectories of modified Rankin Scale (mRS) at different time points.Logistic regression models were used to evaluate the association between SII quartiles and prognosis trajectories at multiple time points (14 days, 1 month, 3 months, 6 months)and prognostic trajectories.Results: Patients in the highest quartile (Q4) of SII had a significantly higher risk of adverse outcomes compared to those in the lowest quartile (Q1). A three-group model was identified as the optimal trajectory model for stroke prognosis. SII was associated with 4.06-fold increased odds (95% CI: 1.64-10.08) of unfavorable prognosis trajectories. Per standard deviation increase in the logarithmic SII, the odds of unfavorable prognosis trajectories were 1.64 (95% CI: 1.18-2.29).Conclusions: Baseline SII is significantly associated with unfavorable outcome trajectories across multiple time points in IS. These findings highlight the potential value of SII as a predictive biomarker for sequential prognosis in stroke patients.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"697-705"},"PeriodicalIF":2.1000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344814/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2540760","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: This study aimed to investigate the association between the systemic immune-inflammation index (SII) and prognosis trajectories in ischemic stroke(IS).

Methods: Patients from two tertiary hospitals in Suzhou were included in this study. SII was calculated as neutrophils×platelets/lymphocytes, and patients were categorized into quartiles based on SII values. Latent class growth modeling (LCGM) was employed to describe the trajectories of modified Rankin Scale (mRS) at different time points.Logistic regression models were used to evaluate the association between SII quartiles and prognosis trajectories at multiple time points (14 days, 1 month, 3 months, 6 months)and prognostic trajectories.

Results: Patients in the highest quartile (Q4) of SII had a significantly higher risk of adverse outcomes compared to those in the lowest quartile (Q1). A three-group model was identified as the optimal trajectory model for stroke prognosis. SII was associated with 4.06-fold increased odds (95% CI: 1.64-10.08) of unfavorable prognosis trajectories. Per standard deviation increase in the logarithmic SII, the odds of unfavorable prognosis trajectories were 1.64 (95% CI: 1.18-2.29).

Conclusions: Baseline SII is significantly associated with unfavorable outcome trajectories across multiple time points in IS. These findings highlight the potential value of SII as a predictive biomarker for sequential prognosis in stroke patients.

查看原文本刊更多论文

全身免疫炎症指数作为脑卒中预后的生物标志物：来自多时间点分析的见解。

目的：本研究旨在探讨缺血性脑卒中（IS）患者全身免疫炎症指数（SII）与预后轨迹的关系。方法：选取苏州市两所三级医院的患者为研究对象。SII计算为neutrophils×platelets/淋巴细胞，并根据SII值将患者分为四分位数。采用潜在类别增长模型（LCGM）描述修正Rankin量表（mRS）在不同时间点的轨迹。采用Logistic回归模型评估SII四分位数与预后轨迹在多个时间点（14天、1个月、3个月、6个月）和预后轨迹之间的关系。结果：SII最高四分位数（Q4）的患者发生不良结局的风险明显高于最低四分位数（Q1）的患者。三组模型是脑卒中预后的最佳轨迹模型。SII与不良预后轨迹的几率增加4.06倍相关（95% CI: 1.64-10.08）。对数SII每增加一个标准差，出现不良预后轨迹的几率为1.64 （95% CI: 1.18-2.29）。结论：在is的多个时间点上，基线SII与不利的结局轨迹显著相关。这些发现突出了SII作为脑卒中患者序贯预后预测生物标志物的潜在价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.